S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
NASDAQ:JAGX

Jaguar Health - JAGX Stock Forecast, Price & News

$0.12
-0.01 (-5.61%)
(As of 12/5/2022 04:20 PM ET)
Add
Compare
Today's Range
$0.11
▼
$0.13
50-Day Range
$0.12
▼
$0.18
52-Week Range
$0.11
▼
$1.89
Volume
7.03 million shs
Average Volume
3.47 million shs
Market Capitalization
$16.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
JAGX stock logo

About Jaguar Health (NASDAQ:JAGX) Stock

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Stock News Headlines

December 5, 2022 | finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related Diarrhea
December 5, 2022 | finance.yahoo.com
Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related Diarrhea
December 5, 2022 | PressReach (Ad)
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
November 29, 2022 | americanbankingnews.com
Jaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.com
November 21, 2022 | finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea
November 21, 2022 | finance.yahoo.com
Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea
November 14, 2022 | finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials
November 14, 2022 | finance.yahoo.com
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials
December 5, 2022 | PressReach (Ad)
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
November 9, 2022 | finance.yahoo.com
Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates
November 4, 2022 | msn.com
Queen Elizabeth’s Personal Jaguar X-Type Estate Is Heading to Auction Later This Month
November 1, 2022 | bizjournals.com
Wolfspeed partners with Jaguar Land Rover to accelerate EV technology
October 27, 2022 | finance.yahoo.com
Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live! to Drive Awareness of Canalevia-CA1 and Participation in Jaguar’s Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
October 26, 2022 | finance.yahoo.com
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
October 17, 2022 | msn.com
Why Jaguar Health Stock Is Popping Off
October 17, 2022 | finance.yahoo.com
European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication
October 14, 2022 | seekingalpha.com
JAGX Jaguar Health, Inc.
October 12, 2022 | finance.yahoo.com
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
October 1, 2022 | finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Reports Voting Results from 2022 Special Meeting of Stockholders
September 29, 2022 | msn.com
Jaguar Land Rover announces ambitious plan to train thousands
September 29, 2022 | finance.yahoo.com
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
September 22, 2022 | finance.yahoo.com
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
September 9, 2022 | msn.com
Watch This Jaguar XJR-12 Scream Around Paul Ricard
August 30, 2022 | msn.com
Jaguar Health Seeks FDA Nod For Cholera Candidate Study
August 30, 2022 | finance.yahoo.com
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
August 27, 2022 | finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
August 25, 2022 | finance.yahoo.com
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
See More Headlines
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Company Calendar

Last Earnings
11/17/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JAGX
CUSIP
N/A
CIK
1585608
Web
www.jaguaranimalhealth.com
Phone
(415) 371-8300
Fax
N/A
Employees
52
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-52,600,000.00
Net Margins
-502.84%
Pretax Margin
-505.58%
Return on Equity
-823.56%
Return on Assets
-104.53%

Debt

Debt-to-Equity Ratio
5.56
Current Ratio
0.94
Quick Ratio
0.69

Sales & Book Value

Annual Sales
$4.34 million
Price / Sales
3.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
0.50

Miscellaneous

Outstanding Shares
145,237,000
Free Float
143,785,000
Market Cap
$16.86 million
Optionable
Not Optionable
Beta
1.67

Key Executives

  • Ms. Lisa A. Conte (Age 63)
    Founder, CEO, Pres & Director
    Comp: $722.54k
  • Mr. Jonathan S. Wolin CPA (Age 60)
    J.D., M.B.A., Chief of Staff, Chief Compliance Officer & Gen. Counsel
    Comp: $478.72k
  • Mr. Ian H. Wendt M.B.A. (Age 54)
    Chief Commercial Officer
    Comp: $431.55k
  • Dr. Steven R. King Ph.D. (Age 64)
    Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
    Comp: $452.61k
  • Ms. Carol R. Lizak (Age 58)
    Chief Financial Officer
  • Dr. Pravin R. Chaturvedi Ph.D. (Age 59)
    Chief Scientific Officer & Chair of Scientific Advisory Board
  • Mr. Peter Hodge
    Sr. Director of Investor Relations, Bus. Devel. & Special Events
  • Dr. Karen J. Brunke Ph.D. (Age 70)
    Exec. VP of Corp. & Bus. Devel.
  • Mr. David Sesin
    Chief Manufacturing Officer
  • Dr. Michael K. Guy D.V.M.
    M.S., Ph.D., VP of Preclinical & Nonclinical Studies

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













JAGX Stock - Frequently Asked Questions

How have JAGX shares performed in 2022?

Jaguar Health's stock was trading at $1.04 at the beginning of 2022. Since then, JAGX shares have decreased by 88.8% and is now trading at $0.1168.
View the best growth stocks for 2022 here.

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023.
View our JAGX earnings forecast.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) posted its earnings results on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company earned $0.63 million during the quarter. Jaguar Health had a negative net margin of 502.84% and a negative trailing twelve-month return on equity of 823.56%. During the same quarter last year, the business posted ($0.63) EPS.

When did Jaguar Health's stock split?

Jaguar Health's stock reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.32%), Renaissance Technologies LLC (0.61%), Citadel Advisors LLC (0.00%) and Group One Trading L.P. (0.00%).
View institutional ownership trends.

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.12.

How much money does Jaguar Health make?

Jaguar Health (NASDAQ:JAGX) has a market capitalization of $16.96 million and generates $4.34 million in revenue each year. The biotechnology company earns $-52,600,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The official website for the company is www.jaguaranimalhealth.com. The biotechnology company can be reached via phone at (415) 371-8300.

This page (NASDAQ:JAGX) was last updated on 12/5/2022 by MarketBeat.com Staff